Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1996 1
1997 1
2000 1
2006 1
2009 1
2013 1
2014 4
2015 3
2016 10
2017 9
2018 4
2019 8
2020 8
2021 12
2022 13
2023 4
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

77 results

Results by year

Filters applied: . Clear all
Page 1
Genomic and immune signatures predict clinical outcome in newly diagnosed multiple myeloma treated with immunotherapy regimens.
Maura F, Boyle EM, Coffey D, Maclachlan K, Gagler D, Diamond B, Ghamlouch H, Blaney P, Ziccheddu B, Cirrincione A, Chojnacka M, Wang Y, Siegel A, Hoffman JE, Kazandjian D, Hassoun H, Guzman E, Mailankody S, Shah UA, Tan C, Hultcrantz M, Scordo M, Shah GL, Landau H, Chung DJ, Giralt S, Zhang Y, Arbini A, Gao Q, Roshal M, Dogan A, Lesokhin AM, Davies FE, Usmani SZ, Korde N, Morgan GJ, Landgren O. Maura F, et al. Among authors: kazandjian d. Nat Cancer. 2023 Dec;4(12):1660-1674. doi: 10.1038/s43018-023-00657-1. Epub 2023 Nov 9. Nat Cancer. 2023. PMID: 37945755
Diagnosed with myeloma before age 40.
Landgren O, Kazandjian D. Landgren O, et al. Among authors: kazandjian d. Blood. 2021 Dec 23;138(25):2601-2602. doi: 10.1182/blood.2021013539. Blood. 2021. PMID: 34940818 Free PMC article. No abstract available.
Immunophenotypic correlates of sustained MRD negativity in patients with multiple myeloma.
Coffey DG, Maura F, Gonzalez-Kozlova E, Diaz-Mejia JJ, Luo P, Zhang Y, Xu Y, Warren EH, Dawson T, Lee B, Xie H, Smith E, Ciardiello A, Cho HJ, Rahman A, Kim-Schulze S, Diamond B, Lesokhin A, Kazandjian D, Pugh TJ, Green DJ, Gnjatic S, Landgren O. Coffey DG, et al. Among authors: kazandjian d. Nat Commun. 2023 Sep 2;14(1):5335. doi: 10.1038/s41467-023-40966-8. Nat Commun. 2023. PMID: 37660077 Free PMC article.
The mutagenic impact of melphalan in multiple myeloma.
Maura F, Weinhold N, Diamond B, Kazandjian D, Rasche L, Morgan G, Landgren O. Maura F, et al. Among authors: kazandjian d. Leukemia. 2021 Aug;35(8):2145-2150. doi: 10.1038/s41375-021-01293-3. Epub 2021 May 19. Leukemia. 2021. PMID: 34012133 Review.
Genomic Classification and Individualized Prognosis in Multiple Myeloma.
Maura F, Rajanna AR, Ziccheddu B, Poos AM, Derkach A, Maclachlan K, Durante M, Diamond B, Papadimitriou M, Davies F, Boyle EM, Walker B, Hultcrantz M, Silva A, Hampton O, Teer JK, Siegel EM, Bolli N, Jackson GH, Kaiser M, Pawlyn C, Cook G, Kazandjian D, Stein C, Chesi M, Bergsagel L, Mai EK, Goldschmidt H, Weisel KC, Fenk R, Raab MS, Van Rhee F, Usmani S, Shain KH, Weinhold N, Morgan G, Landgren O. Maura F, et al. Among authors: kazandjian d. J Clin Oncol. 2024 Jan 9:JCO2301277. doi: 10.1200/JCO.23.01277. Online ahead of print. J Clin Oncol. 2024. PMID: 38194610
77 results